[CLINICAL EXPERIENCE WITH THE NEW PERORAL GESTAGEN, 16-METHYLENE-6-DEHYDRO-17-ALPHA-ACETOXYPROGESTERONE (MDAP)].
D004358:Drug Therapy; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones; D008599:Menstruation Disturbances; D011372:Progestins; D014116:Toxicology
D006908:Hydroxyprogesterones; D011372:Progestins; C011025:16-methylene-17 alpha-acetoxyprogesterone
DRUG THERAPY; MENSTRUATION DISORDERS; PROGESTATIONAL HORMONES; TOXICOLOGIC REPORT
KLINISCHE ERFANRUNGEN MIT DEM NEUEN PERORALEN GESTAGEN 16-METHYLEN-6-DEHYDRO-17-ALPHA-AZETOXYPROGESTERON (MDAP)